The “Female Viagra” Label Is Broader Than It Used to Be

The label changed the age conversation

For years, flibanserin was described in a narrow way: a daily treatment for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

That description is now outdated in the United States.

The current Addyi prescribing information lists a December 2025 major change to “Indications and Usage” and states that Addyi is indicated for women less than 65 years old with acquired, generalized HSDD. The label defines this as low sexual desire causing marked distress or interpersonal difficulty, not explained by a medical or psychiatric condition, relationship problems, medication effects, or another drug substance. (FDA Access Data)

That is the current-label issue behind Female Viagra flibanserin postmenopausal under 65 approval.

The drug is still not a general libido enhancer. But the eligible population is no longer framed only around premenopausal status.

Postmenopause does not make the diagnosis automatic

The expanded label does not mean that every woman with lower desire after menopause has HSDD.

That distinction matters.

Menopause can affect libido through vaginal dryness, pain with sex, sleep disruption, vasomotor symptoms, mood changes, body-image changes, relationship stress, medications, chronic disease, and hormone changes. HSDD is more specific: the low desire is acquired, generalized, distressing, and not better explained by those other causes. (FDA Access Data)

The official Addyi site now describes the drug as a prescription medicine for women under 65 with HSDD who previously did not have low sexual desire, whose low desire occurs regardless of sexual activity type, situation, or partner, and whose symptoms are troubling to them. It also states that the problem should not be due to medical or mental-health issues, relationship problems, medication, or drug use. (Addyi® (flibanserin) | Official Site)

That diagnostic boundary is the important part.

The label expansion does not remove the need to investigate the cause.

It is still not on-demand

The phrase “Female Viagra” can mislead patients.

Viagra is usually taken before sex and works through genital blood-flow physiology. Flibanserin is different. It is taken once daily at bedtime and acts centrally on neurotransmitter pathways linked to sexual desire.

The current label recommends 100 mg once daily at bedtime. It explains that bedtime dosing is used because taking the drug during waking hours increases risks of hypotension, syncope, accidental injury, and central nervous system depression such as somnolence and sedation. (FDA Access Data)

That is not an on-demand sexual-performance model.

A woman does not take flibanserin shortly before sex and expect an immediate physical response. It is assessed over time.

The 8-week rule is part of the drug’s identity

The updated label gives a clear stopping point: discontinue Addyi after 8 weeks if the patient does not report improvement in HSDD symptoms. (FDA Access Data)

This is clinically important because low desire can be emotionally loaded. Patients may continue a medication because they hope it will eventually work, or because they feel they have few options. The label creates a practical boundary: if there is no improvement after 8 weeks, the drug should not simply be continued indefinitely.

That makes flibanserin different from casual supplement-style libido products.

It has a defined dose, a defined bedtime schedule, a defined diagnostic target, and a defined failure point.

The safety rules did not disappear

The indication became broader, but the safety profile did not become casual.

The current label warns that Addyi can cause central nervous system depression, including somnolence and sedation. In five 24-week placebo-controlled trials of premenopausal women with HSDD, somnolence, sedation, or fatigue occurred in 21% of patients treated with 100 mg Addyi once daily at bedtime, compared with 8% on placebo. (FDA Access Data)

The label also advises patients to avoid activities requiring full alertness, such as driving or operating machinery, until at least 6 hours after each dose and until they know how Addyi affects them. (FDA Access Data)

That warning is easy to overlook if the product is framed as a “desire pill.” It is still a CNS-active medication with hypotension, syncope, sedation, alcohol, liver, and interaction considerations.

The practical takeaway

Female Viagra should not be understood through the male Viagra model.

Flibanserin is not a fast physical performance drug. Its current U.S. label covers women under 65 with acquired, generalized HSDD, including a broader population than the original premenopausal-only framing. But the diagnosis remains narrow, the dosing is daily at bedtime, the response should be judged by 8 weeks, and the safety rules remain substantial.

The label became broader.

The prescribing decision did not become simpler.

Disclaimer

This article is for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Flibanserin or any medication for low sexual desire should be used only under the guidance of a qualified healthcare professional.

References

1. FDA-approved Addyi prescribing information, revised December 2025: updated indication for women less than 65 years of age, bedtime dosing, safety warnings, and 8-week discontinuation rule. (FDA Access Data)

2. FDA label search result summary confirming the current indication for women less than 65 years with acquired, generalized HSDD. (FDA Access Data)

3. Official Addyi patient information: HSDD definition, women under 65, and limitation that Addyi is not for men or sexual performance enhancement. (Addyi® (flibanserin) | Official Site)

4. Urology Times report on the December 2025 FDA expansion to include postmenopausal women younger than 65. (Urology Times)